PBT2 — разлика између измена

PBT2
Nazivi
	IUPAC naziv 5,7-Dihloro-2-[(dimetilamino)metil]kvinolin-8-ol
Identifikacija
3D model (Jmol)	interaktivna slika;
ChemSpider	8191585;
PubChem C ID	10016012;
UNII	Q7K6GJQ4O4 ;
	SMILES CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl; ; ; ; ; ;
Svojstva
Hemijska formula	C12H12Cl2N2O
Molarna masa	271,14 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

Новија измена →

Садржај обрисан Садржај додат

ВизуелноВикитекст

Инлајн

Верзија на датум 3. октобар 2016. у 06:12

PBT2 je ekperimentalni kandidat leka. On je druga generacija 8-hidroksihinolinskog analoga^[3] koji bi trebalo da bude zamena za kliokvinol i potencijalni tretman za Alchajmerovu bolest.^[4]

Klinička ispitivanja

PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals,^[5]^[6] and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia.^[7] The drug also missed efficacy goals for Huntington's disease.^[8]^[9]

Reference

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Adlard, Paul A.; Cherny, Robert A.; Finkelstein, David I.; Gautier, Elisabeth; Robb, Elysia; Cortes, Mikhalina; Volitakis, Irene; Liu, Xiang; et al. (2008). „Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs is Associated with Decreased Interstitial Aβ”. Neuron. 59 (1): 43—55. PMID 18614028. doi:10.1016/j.neuron.2008.06.018.
^ Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Leong, Su Ling; Perez, Keyla; et al. (2010). „Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease”. Cell. 142 (6): 857—67. PMC 2943017 . PMID 20817278. doi:10.1016/j.cell.2010.08.014. Генерални сажетак – ScienceDaily (2010-09-10).
^ „Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study”. Bloomberg News. 2014-03-31.
^ „PBT2 Takes a Dive in Phase 2 Alzheimer's Trial”. 2014.
^ „There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia”. Cochrane Database of Systematic Reviews: Plain Language Summaries. PubMed Health.
^ „Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles”. thestreet.com.
^ Huntington Study Group Reach2HD Investigators (2015). „Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial”. The Lancet Neurology. 14 (1): 39—47. PMID 25467848. doi:10.1016/S1474-4422(14)70262-5.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Adlard, Paul A.; Cherny, Robert A.; Finkelstein, David I.; Gautier, Elisabeth; Robb, Elysia; Cortes, Mikhalina; Volitakis, Irene; Liu, Xiang; et al. (2008). „Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs is Associated with Decreased Interstitial Aβ”. Neuron. 59 (1): 43—55. PMID 18614028. doi:10.1016/j.neuron.2008.06.018.

[4] Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Leong, Su Ling; Perez, Keyla; et al. (2010). „Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease”. Cell. 142 (6): 857—67. PMC 2943017 . PMID 20817278. doi:10.1016/j.cell.2010.08.014. Генерални сажетак – ScienceDaily (2010-09-10).

[5] „Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study”. Bloomberg News. 2014-03-31.

[6] „PBT2 Takes a Dive in Phase 2 Alzheimer's Trial”. 2014.

[7] „There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia”. Cochrane Database of Systematic Reviews: Plain Language Summaries. PubMed Health.

[8] „Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles”. thestreet.com.

[9] Huntington Study Group Reach2HD Investigators (2015). „Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial”. The Lancet Neurology. 14 (1): 39—47. PMID 25467848. doi:10.1016/S1474-4422(14)70262-5.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]